The Androtriol Injection for the Treatment of Acute Ischemic Stroke
A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 300 participants.
Also called NCT06679322
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 300 participants
- Sponsor
- Registry
-
NCT06679322
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT06679322. Randomized; quadruple masking; primary purpose treatment. Start 2024-10-31 (anticipated); primary completion 2025-09-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Androtriol Injection for the Treatment of Acute Ischemic Stroke
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- Androtriol Injection (High-dose group)
- Intervention (Drug)
- Androtriol Injection (Low-dose group)
- Intervention (Drug)
- Hydroxypropyl-β-cyclodextrin injection
- Lead sponsor
- Beijing Tiantan Hospital
Record details
- Record id
cardio:ct-nct06679322- Content hash
6b65aabe92a6c718a39a60ca1e4ed41a6d7524f1cf8d848fe058d6e34d334e2f